Johnson & Johnson’s JNJ MedTech unit has temporarily paused sales of Varipulse, its pulsed field ablation (PFA) therapy to ...
The temporary pause will allow the company to investigate four neurovascular events seen in an external validation study.
Johnson & Johnson announced that on January 5, “out of an abundance of caution,” Johnson & Johnson MedTech temporarily paused the U.S.
Johnson & Johnson MedTech announced that it has temporarily paused the United States External Evaluation and all United Stat ...
After a busy 2024, experts called out competition in soft tissue robotics, uncertainty from a Trump White House and continued ...
Bernstein lowered the firm’s price target on Johnson & Johnson to $160 from $177 and keeps a Market Perform rating on the shares as part of ...
Qure.ai announced today that it appointed Jim Mercadante, a 25-year medtech veteran, as its new chief commercial officer (CCO ...
We came across a bullish thesis on Johnson & Johnson (NYSE:JNJ) on Business Model Mastery Substack by The Antifragile ...
Boston Scientific is diving into the field of intravascular lithotripsy, with a $664 million deal to pick up Bolt Medical and ...